Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allergic Reactions02:06

Allergic Reactions

31.7K
Overview
31.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Otitis Media With Effusion (OME) and Eustachian Tube Dysfunction: The Role of Allergy and Immunity-An EAACI Position Paper.

Allergy·2025
Same author

EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR.

Frontiers in allergy·2025
Same author

House dust mite immunotherapy: A real-world, prescription data-based analysis.

Clinical and translational allergy·2024
Same author

Response to Correspondence to "Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy".

Allergy·2024
Same author

Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy.

Allergy·2023
Same author

An international Delphi study on the burden of allergic rhinoconjunctivitis and urticaria and the role of bilastine among current treatment options.

Expert review of clinical immunology·2023
Same journal

Update of the evidence- and consensus-based S3 guideline on atopic dermatitis: Systemic therapy with biologics or Janus kinase inhibitors and specific aspects of systemic therapy in pregnancy and lactation.

Allergologie select·2026
Same journal

Resolution of childhood wheat allergy through evolution into WALDA? A case report.

Allergologie select·2026
Same journal

T-cell mechanisms in atopic dermatitis.

Allergologie select·2026
Same journal

Cefazolin as an alternative in patients with a history of penicillin or β-lactam antibiotic allergy: A case overview.

Allergologie select·2026
Same journal

Does the teicoplanin skin test predict IgE-mediated hypersensitivity?

Allergologie select·2026
Same journal

Expert consensus on the long-term use of lanadelumab in hereditary angioedema: Toward harmonized care.

Allergologie select·2026
See all related articles

Related Experiment Video

Updated: Dec 26, 2025

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

2.9K

Allergen immunotherapy phase II trials: Challenges in dose finding.

J Kleine-Tebbe1, S Kaul2, R Mösges3

  • 1Allergy and Asthma Center Westend, Berlin.

Allergologie Select
|March 17, 2020
PubMed
Summary
This summary is machine-generated.

Phase II studies are crucial for determining optimal allergen immunotherapy (AIT) doses. Current trials face challenges in dose selection and data interpretation, impacting AIT product development and market approval in Europe.

Keywords:
allergen challengeallergen-specific immunotherapydesensitizationdose finding studiesefficacyphase II studies

More Related Videos

Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

9.2K
Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE
07:10

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE

Published on: April 21, 2019

16.8K

Related Experiment Videos

Last Updated: Dec 26, 2025

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
08:47

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber

Published on: March 3, 2023

2.9K
Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

9.2K
Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE
07:10

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE

Published on: April 21, 2019

16.8K

Area of Science:

  • Allergy and Immunology
  • Pharmacology
  • Clinical Trials

Background:

  • Phase II studies are essential for defining optimal doses in allergen immunotherapy (AIT), balancing efficacy and safety.
  • EMA guidelines mandate phase II trials for new AIT products under the German Therapy Allergen Ordinance (TAV).
  • Challenges include dose selection, placebo effect minimization, patient numbers, and cost-effectiveness.

Purpose of the Study:

  • To evaluate the role and challenges of phase II studies in establishing optimal doses for AIT products.
  • To highlight the necessity of robust phase II data for subsequent phase III trials and regulatory approval.
  • To emphasize the need for improved data analysis and transparency in AIT phase II trials.

Main Methods:

  • Review of existing phase II study designs and endpoints for AIT.
  • Analysis of challenges in dose-response assessment and placebo effect control.
  • Consideration of regulatory requirements (EMA, TAV) and Paul-Ehrlich-Institute perspectives.

Main Results:

  • Phase II trials are critical for dose selection but face significant challenges.
  • Current phase II trials for TAV products have not consistently confirmed marketed AIT doses.
  • There is a need for more detailed individual patient data to improve interpretation and understanding of AIT outcomes.

Conclusions:

  • Phase II studies are indispensable for AIT development, guiding dose selection for pivotal trials.
  • Improved methodology and data transparency in phase II trials are necessary for reliable AIT efficacy evidence.
  • These findings impact all manufacturers of AIT products in Germany and Europe, influencing future development and regulatory submissions.